Evidence
CAnimal replicated
The Zinc Dependency — The Most Important Fact
Thymulin is biologically inactive without zinc. Zinc binding induces a specific three-dimensional conformation in thymulin (confirmed by NMR) that allows high-affinity receptor interaction and downstream immune signaling. Without adequate zinc: (1) already-secreted thymulin circulates in inactive apo-form; (2) T-cell maturation signaling is reduced; (3) immunosenescence accelerates. The critical consequence: a significant portion of age-related thymulin 'deficiency' actually reflects zinc deficiency, not reduced thymulin production. Zinc supplementation in zinc-deficient elderly adults restores thymulin bioactivity by converting circulating apo-thymulin to the active Zn-thymulin form.
Age-Related Decline
Thymulin plasma levels decline with thymic involution — from detectable levels in young adults to near-undetectable in most adults over 60. Crucially, this decline has TWO components: (1) Structural: genuine reduction in thymulin production as thymic epithelial mass decreases with involution; (2) Functional: zinc deficiency (prevalent in 30-40% of elderly adults) converts active Zn-thymulin to inactive apo-thymulin. The zinc-mediated component is REVERSIBLE through zinc supplementation. The structural component requires either exogenous thymulin or other thymic restoration strategies.
Human Evidence — The Honest Summary
Two human studies are cited for thymulin: (1) Bordigoni et al. (1982, Lancet): synthetic thymulin administered to immunodeficient children improved cellular immunity and IgA production. This is the ONLY published human interventional study for exogenous thymulin. It is 40+ years old. No controlled replication has been published. (2) Prasad et al. (1988, Journal of Clinical Investigation): zinc depletion in human volunteers reduced thymulin activity; zinc supplementation reversed it. This is a zinc study confirming the dependency mechanism, not a thymulin administration study. The human evidence grade for exogenous thymulin is Grade D — one ancient uncontrolled case series.
The Zinc Strategy — The Practical Bottom Line
The most evidence-supported thymulin intervention in community use is: check and correct zinc status. Zinc-deficient elderly adults: Mocchegiani 1995 showed oral zinc supplementation (15 mg/day) significantly restored thymulin bioactivity AND NK cell function within 1-3 months. The mechanism: converts pre-existing circulating apo-thymulin to active Zn-thymulin (does not require new thymulin synthesis). This means zinc supplementation works even when the thymus has significantly involuted — as long as some apo-thymulin is still circulating. For zinc-sufficient individuals: additional zinc above requirements does NOT further increase thymulin. Benefit is deficiency correction only.
Novel Applications
Emerging animal evidence suggests thymulin has activities beyond classical T-cell immunomodulation: (1) Anti-inflammatory and analgesic: Nasseri et al. 2019 (International Immunopharmacology) — thymulin attenuates inflammatory pain by modulating spinal NF-κB/cytokine signaling. (2) Neuroprotection: thymulin reduces neuroinflammation; BBB protection in MS models. (3) Lung disease: immunomodulatory role documented in experimental lung injury models. (4) Gene therapy: AAV-thymulin vectors show remarkable results in animal models of arthritis and inflammatory pain — active current research area but purely preclinical. All novel applications: Grade D (animal/in vitro). No human trial for any of these applications.
Thymulin vs Thymosin Alpha-1 vs Thymalin
Three different thymic compounds frequently confused: Thymulin: 9-aa zinc-dependent endogenous hormone; T-cell maturation; single defined peptide; very limited human evidence. Thymosin Alpha-1: 28-aa synthetic analog of the prothymosin alpha precursor; TLR2/TLR9 activation; multiple RCTs (Grade A for HBV); approved in 37+ countries as Zadaxin. Thymalin: a mixture of thymic peptide bioregulators developed in the Khavinson tradition; complex multi-peptide preparation; separate chapter in this reference. These three are not interchangeable or pharmacologically equivalent.